| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
Purity: ≥98%
Amantadine HCl (EXP-105-1; GP 38026; ADS5102; Influenol; Midantan; Midantane; Mydantane; NSC 83653; Symadine; Symmetrel; Trivaline; Virasol; Viregyt; Virofral; Virosol), the hydrochloride salt of amantadine, is an approved medication used to treat or prevent infections of the respiratory tract caused by a certain virus. Amantadine has been approved by the FDA to be used as an antiviral and an antiparkinsonian medication.
| Targets |
CDK2; Bcl-2; Bax
|
|---|---|
| ln Vitro |
Amantadine hydrochloride (0-500 μM, 26 hours) inhibits SARS-CoV-2 replication with IC50 concentrations between 83 and 119 μM [4]. Amantadine hydrochloride (0-100 μg/mL, 24-72 h) significantly inhibits HepG2. Amantadine hydrochloride (0-75 μg/mL, 48 h) blocks the cell cycle in the G0/G1 phase and induces cell swelling [6]. Amantadine hydrochloride (0-75 μg) and swelling of SMMC-7721 cells [6]. /mL, 48 h) can reduce cell cycle-related genes and proteins (cyclin D1, cyclin E and CDK2), reduce Bcl-2 and increase Bax protein and mRNA levels [6]. Cell Viability Assay[4] Cell Line: Vero E6 Cell Concentration: 500 µM, 100 µM, 20 µM, 4 µM and 8 nM Incubation time: 26 hours Results: Concentration of viral nucleic acid in the supernatant after 26 hours of infection at 10°C Reduced dependence (IC50=83 µM) -500 µM. Results in a concentration-dependent reduction of viral nucleic acid in the cytoplasm (IC50=119 µM) 26 hours post-infection. Cell proliferation assay[6] Cell lines: Human HCC cell lines (HepG2 and SMMC-7721) and normal liver cells (L02 cells) Concentrations: 0, 1, 2, 5, 10, 25, 50 and 100 µg/mL Incubation time : 24, 48 and 72 hours Results: Inhibited cell proliferation in a time- and dose-dependent manner in HepG2 and SMMC-7721 cells. Cell cycle analysis[6] Cell lines: HepG2 and SMMC-7721 Cell concentrations: 0, 10, 25, 50 and 75 µg/mL Incubation time: 48 hours Results: Significant increase in the number of HepG2 and SMMC-7721 cells in G0/G1 phase in a dose-dependent manner, and significantly reduced the number of HepG2 cells in the S phase. Apoptosis analysis[6] Cell lines: HepG2 and SMMC-7721 Cell concentrations: 0, 10, 25, 50 and 75 µg/mL Incubation time: 48 hours Results: Significant increase in the percentage of apoptotic HepG2 and SMMC-7721 cells (early- and late-stage apoptosis) in a dose-dependent manner. Western Blot Analysis[6] Cell lines: HepG2 and SMMC-7721 Cell concentrations: 0, 10, 25, 50 and 75 µg/mL Incubation time: 48 h Results: showed downregulation of cyclin D1, cyclin E and CDK2, and showed that HepG2 and Bcl-2 levels were reduced and Bax levels were increased in SMMC-7721 cells. RT-PCR[6] Cell lines: HepG2 and SMMC-7721 Cell concentrations: 0, 10, 25, 50 and 75 µg/mL Incubation time: 48 hours Results: Showed an increase in Bax and a decrease in Bcl-2 gene.
|
| ln Vivo |
Amantadine hydrochloride (25 mg/kg, IP, once daily for 3 days) inhibits neuromodulation and learning and memory impairments caused by conditioning [5]. Animal model: Fischer 344 rats (4 months old, male, 290-330 g, 15 rats per group) [5] Dosage: 25 mg/kg Administration method: IP, once daily for 3 consecutive days (surgery 15 minutes before the first administration) Results: Inhibition of neuroinflammation and learning and memory impairment caused by surgery, increased GDNF (glial cell line-derived neurotrophic factor) and glial fibrillary acidic protein (star) in the hippocampus morphocyte markers) colocalized.
|
| Cell Assay |
Cell Line: Vero E6 cells
Concentration: 500 µM, 100 µM, 20 µM, 4 µM, and 8 nM Incubation Time: 26 h Result: Caused a concentration-dependent reduction (IC50=83 µM) of viral nucleic acids in the supernatant 26 h after infection at 10-500 µM. Caused a concentration-dependent reduction (IC50=119 µM) of viral nucleic acids in the cytosol 26 h after infection. |
| Animal Protocol |
Fischer 344 rats (Four-month old, male, 290-330 g, 15 rats each group)
25 mg/kg Administration: IP, once daily for 3 days (the first dose at 15 min before surgery) |
| References |
| Molecular Formula |
C10H18CLN
|
|
|---|---|---|
| Molecular Weight |
187.7
|
|
| Exact Mass |
187.11
|
|
| Elemental Analysis |
C, 63.99; H, 9.67; Cl, 18.89; N, 7.46
|
|
| CAS # |
665-66-7
|
|
| Related CAS # |
Amantadine; 768-94-5; Amantadine sulfate; 31377-23-8
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1C2CC3CC1CC(C2)(C3)N.Cl
|
|
| InChi Key |
WOLHOYHSEKDWQH-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C10H17N.ClH/c11-10-4-7-1-8(5-10)3-9(2-7)6-10;/h7-9H,1-6,11H2;1H
|
|
| Chemical Name |
adamantan-1-amine;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3277 mL | 26.6383 mL | 53.2765 mL | |
| 5 mM | 1.0655 mL | 5.3277 mL | 10.6553 mL | |
| 10 mM | 0.5328 mL | 2.6638 mL | 5.3277 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06052787 | Recruiting | Drug: Cerebrolysin Drug: amantadine sulfate |
Traumatic Brain Injury | Ain Shams University | September 1, 2023 | Phase 3 |
| NCT05140148 | Recruiting | Drug: Amantadine Drug: Placebo |
Stroke, Ischemic Stroke Hemorrhagic |
University of Pennsylvania | February 1, 2022 | Phase 2 |
| NCT05667077 | Not yet recruiting | Drug: Amantadine | Post-COVID-19 Syndrome | Shahid Beheshti University of Medical Sciences |
December 26, 2022 | Phase 2 |
| NCT06055244 | Not yet recruiting | Drug: Amantadine | Long COVID Post-COVID19 Condition |
Ohio State University | October 15, 2023 | Phase 1 |
| NCT04530006 | Recruiting | Diagnostic Test: Amantadine Hydrochloride |
Glioblastoma Multiforme | CancerCare Manitoba | December 2, 2020 | Not Applicable |
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
